Live- In Person Portland,OR Meeting

1.0 CME/NCPD Credit
Click Here to complete the pre-assessment

This CE activity is intended for oncology nurses and nurse practitioners who provide care for individuals with non-small cell lung cancer (NSCLC).

After completing this CE activity, the participant should be better able to:

  • Evaluate the implications of test results for prognosis, treatment selection, and patient education
  • Collaborate with team members to apply guidelines and best practices for biomarker testing and address barriers to testing
  • Assess emerging safety and efficacy data for new and novel targeted therapies, including those to manage acquired resistance
  • Plan strategies to prevent and mitigate AEs of targeted therapy, including engaging patients of diverse background in prevention and monitoring

Joint Accreditation with Commendation Logo In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hours and 1.0 contact hours in the area of pharmacology.

Supporter

The activity is supported by educational funding provided by Amgen and by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pre-Assessment

Please enable JavaScript in your browser to complete this form.
Less than _____% of patients in the US receive recommended biomarker testing for advanced stage lung cancer.
A 65-year-old Black male has an EGFR exon 20-positive NSCLC with disease progression and started on amivantamab as a second-line therapy. Which of its common adverse events (AEs) may present differently because of his demographic?
After several months of treatment with gefitinib, you find that your patient’s disease has progressed. Laboratory results confirm an EGFR T790M resistant mutation. What treatment would be considered in this scenario?
In the LIBRETTO-001 trial, selpercatinib yielded an 84.1% overall response rate (ORR) and a 20.1 median duration of response (DOR), leading to its FDA approval, for which population?
Your patient is a non-smoker with NSCLC. Unfortunately, limited tissue was retrieved in the initial biopsy, and you decide to order a liquid biopsy for biomarker testing. She has received a negative result. What is your interpretation of this result?
Mr. Jones is a 75-year-old man with advanced NSCLC. Comprehensive molecular and PD-L1 IHC testing have been ordered. IHC testing reveals high PD-L1 expression. You are still waiting on the results from NGS. Mr. Jones is ready to begin treatment now. What are your next steps?
Mr. Smith is 46 years old and has metastatic NSCLC with disease progression after chemotherapy. Biomarker testing showed he was positive for EFGR exon20 insertion mutation. What therapy would you recommend for Mr. Smith?
Mr. Johnson is a 75-year-old man with advanced NSCLC. Comprehensive molecular and PD-L1 IHC testing reveals that is RET-fusion positive and has high PD-L1 expression. What are your next steps?
A 55-year-old woman weighing 52 kg with a history of hypertension and nausea (both currently controlled) was recently diagnosed with Stage IV NSCLC with metastases to the liver. Biomarker analysis confirmed RET fusionpositive mutation. She is started on selpercatinib. Based on her medical history and treatment plan, what is the best strategy for preventing and monitoring for AEs?
Your patient has developed pneumonitis while on targeted therapy for advanced NSCLC. What is the first step in your mitigation strategy?
Go to Event Site
Scroll to Top